RCKT
Rocket Pharmaceuticals is a biopharmaceutical company focused on developing gene and molecular therapies to treat rare genetic diseases, with a particular emphasis on cardiac and other organ-specific conditions. The company conducts research and clinical trials globally, including programs for Danon disease and other rare cardiovascular disorders, with corporate and R&D headquarters in Cranbury, New Jersey and presence in New York. Their work aims to move gene therapies from research to approved treatments that address root causes of disease and improve patient outcomes. They also emphasize patient resources and collaboration with healthcare professionals and regulatory bodies to advance rare-disease therapeutics.
No recent deals for this company.